Literature DB >> 11149986

Dysregulation of the IgE/Fc epsilon RI network in HIV-1 infection.

G Marone1, G Florio, A Petraroli, A de Paulis.   

Abstract

Serum IgE levels are increased in adults and children with HIV-1 infection and could be a marker of poor prognosis. Allergic reactions and adverse reactions to drugs are also increased in HIV-1-infected individuals. An imbalance between a T(H)1-like and a T(H)2-like cytokine profile has been documented in HIV-1 infection. We have found that HIV-1 gp120 from different clades is a potent stimulus for histamine and cytokine (IL-4 and IL-13) release from basophils. Gp120 acts as a viral superantigen, interacting with the V(H)3 region of IgE to induce mediator release from human Fc epsilon RI(+) cells. Human basophils and mast cells express the chemokine receptor CCR3, which binds the chemokines eotaxin and RANTES. By interacting with the CCR3 receptor on Fc epsilon RI(+) cells, HIV-1 Tat protein is a potent chemoattractant for human basophils and lung mast cells. Tat protein also induced IL-4 and IL-13 release from basophils. Preincubation of basophils with Tat protein upregulated the surface expression of the CCR3 receptor. Extracellular Tat can influence the directional migration of human Fc epsilon RI(+) cells, the expression of chemokine receptor CCR3, and the release of T(H)2 cytokines. Because Tat protein is actively released by HIV-1-infected cells, our results indicate a novel mechanism by which Fc epsilon RI(+) cells are rendered more susceptible to infection with CCR3-tropic HIV-1 isolates; that is, two HIV-1 proteins, gp120 and Tat, trigger the release of cytokines critical for T(H)2 polarization from Fc epsilon RI(+) cells, and Tat upregulates beta-chemokine receptor CCR3 on these cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11149986     DOI: 10.1067/mai.2001.111589

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

Review 1.  Mast cell mediator responses and their suppression by pathogenic and commensal microorganisms.

Authors:  Hae Woong Choi; Soman N Abraham
Journal:  Mol Immunol       Date:  2014-03-11       Impact factor: 4.407

2.  Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.

Authors:  Brian M Jones; Susan Ss Chiu; Wilfred Hs Wong; Wilina Wl Lim; Yu-Lung Lau
Journal:  J Int AIDS Soc       Date:  2005-05-03       Impact factor: 5.396

3.  Correlation between eosinophils and protection against reinfection with Schistosoma mansoni and the effect of human immunodeficiency virus type 1 coinfection in humans.

Authors:  Lisa M Ganley-Leal; Pauline N Mwinzi; Catherine B Cetre-Sossah; Julius Andove; Allen W Hightower; Diana M S Karanja; Daniel G Colley; W Evan Secor
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

4.  Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.

Authors:  Brian M Jones; Susan S S Chiu; Wilfred H S Wong; Wilina W L Lim; Yu-lung Lau
Journal:  MedGenMed       Date:  2005-05-03

5.  Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy.

Authors:  Michaeline L Hebron; Irina Lonskaya; Paul Olopade; Sandra T Selby; Fernando Pagan; Charbel E-H Moussa
Journal:  J Clin Cell Immunol       Date:  2014-09-30

6.  Serum IgE levels in Korean patients with human immunodeficiency virus infection.

Authors:  Jee Hyun Park; Byung Chul Shin; Byung Hun Do; Jong Taek Oh; Jong Myung Lee; Shin Woo Kim; Nung Soo Kim
Journal:  Korean J Intern Med       Date:  2002-06       Impact factor: 2.884

7.  HIV-1 Nef promotes migration and chemokine synthesis of human basophils and mast cells through the interaction with CXCR4.

Authors:  Francesca Wanda Rossi; Nella Prevete; Felice Rivellese; Antonio Lobasso; Filomena Napolitano; Francescopaolo Granata; Carmine Selleri; Amato de Paulis
Journal:  Clin Mol Allergy       Date:  2016-11-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.